LAX.SH
AJANTA PHARMA LIMITED·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
3,270.6
+0.31%52W Range
Market Cap
₹40,869.10 Cr
Traded: ₹18.90 Cr (0.05%) 0.0x
Free Float: ₹2,873.10 Cr (0.66% of FF traded)
Volume · 60D trend
58.12 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +12.0% | +14.0% | +13.0% | -- | +20.0% | Stable |
| ROE | +23.0% | +23.0% | +25.0% | -- | -- | Stable |
| Return | +11.0% | +18.0% | +27.0% | +23.0% | -- | Stable |
| Profit | +10.0% | +12.0% | +24.0% | -- | +22.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,626 | 1,422 | 1,375 | 1,354 | 1,303 | 1,170 | 1,146 | 1,187 | 1,145 | 1,054 | 1,105 | 1,028 | 1,021 | 882 | 972 |
| Expenses | 1,202 | 1,088 | 993 | 1,026 | 951 | 873 | 825 | 875 | 815 | 776 | 791 | 738 | 750 | 732 | 802 |
| Operating Profit | 424 | 333 | 382 | 328 | 351 | 297 | 321 | 311 | 330 | 278 | 314 | 291 | 271 | 149 | 170 |
| Other Income | 71 | 61 | 25 | 59 | 26 | 18 | 30 | 19 | 26 | 36 | 14 | 21 | 32 | 37 | 35 |
| Interest | 3 | 2 | 5 | 3 | 5 | 6 | 8 | 6 | 1 | 2 | 2 | 2 | 1 | 1 | 3 |
| Depreciation | 44 | 45 | 44 | 43 | 41 | 40 | 36 | 34 | 34 | 34 | 34 | 34 | 33 | 33 | 33 |
| Profit Before Tax | 447 | 347 | 359 | 341 | 331 | 269 | 307 | 290 | 322 | 278 | 291 | 276 | 269 | 152 | 168 |
| Tax % | 25.0% | 23.0% | 24.0% | 24.0% | 23.0% | 16.0% | 24.0% | 25.0% | 24.0% | 27.0% | 28.0% | 29.0% | 23.0% | 20.0% | 20.0% |
| Net Profit | 334 | 267 | 274 | 260 | 255 | 225 | 233 | 216 | 246 | 203 | 210 | 195 | 208 | 122 | 135 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 26.8 | 21.4 | 21.9 | 20.8 | 20.4 | 18.0 | 18.6 | 17.3 | 19.7 | 15.8 | 16.4 | 15.2 | 16.2 | 9.5 | 10.5 |
| Sales Growth (YoY) | 24.8% | 21.5% | 20.0% | 14.1% | 13.8% | 11.0% | 3.7% | 15.5% | 12.1% | 19.5% | 13.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 14.3% | 3.4% | 1.6% | 3.9% | 11.4% | 2.1% | -3.5% | 3.7% | 8.6% | -4.6% | 7.5% | 0.7% | 15.8% | -9.3% | -- |
| OP Growth (YoY) | 20.8% | 12.1% | 19.0% | 5.5% | 6.4% | 6.8% | 2.2% | 6.9% | 21.8% | 86.6% | 84.7% | -- | -- | -- | -- |
| OP Growth (QoQ) | 27.3% | -12.8% | 16.5% | -6.6% | 18.2% | -7.5% | 3.2% | -5.8% | 18.7% | -11.5% | 7.9% | 7.4% | 81.9% | -12.4% | -- |
| Profit Growth (YoY) | -- | 18.0% | 18.0% | 20.0% | 4.0% | 11.0% | 11.0% | 11.0% | 18.0% | 66.0% | 56.0% | 25.0% | 19.0% | -19.0% | -30.0% |
| EPS Growth (YoY) | 30.9% | 18.4% | 17.5% | 20.2% | 3.9% | 14.0% | 13.7% | 13.7% | 21.2% | 65.8% | 56.1% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 25.3% | -2.6% | 5.2% | 1.9% | 13.4% | -3.3% | 7.6% | -11.9% | 24.4% | -3.5% | 7.5% | -6.2% | 70.2% | -9.1% | -- |
| OP Margin | 26.1% | 23.4% | 27.8% | 24.2% | 26.9% | 25.4% | 28.0% | 26.2% | 28.8% | 26.4% | 28.4% | 28.3% | 26.5% | 16.9% | 17.5% |
| Net Margin | 20.5% | 18.8% | 19.9% | 19.2% | 19.6% | 19.2% | 20.3% | 18.2% | 21.5% | 19.3% | 19.0% | 19.0% | 20.4% | 13.8% | 13.9% |
| Material Cost % | -- | 21.4% | 20.8% | 23.4% | 21.2% | 24.2% | 22.5% | 22.1% | 23.4% | 25.1% | 26.6% | 24.9% | 24.7% | 27.3% | 27.7% |
| Employee Cost % | -- | 24.0% | 24.0% | 23.4% | 23.3% | 23.9% | 23.1% | 22.0% | 24.8% | 22.1% | 20.9% | 21.6% | 20.9% | 25.4% | 19.8% |
| P/S | 7.07 | 7.78 | 6.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 36.00 | 40.18 | 35.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 9.03 | 9.37 | 8.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee ....
Pls find enclosed Earnings Conference Call Intimation.
Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve Unaudited consolidated and standalone ....
Pls find enclosed Certificate as per Reg 74(5) of SEBI (DP) Regulations.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 06, 2026 for Aayush Agrawal, trustee ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship Ltd
Pls find enclosed herewith Sustainability Report for FY 2026.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 28, 2026 for Aayush Agrawal, ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 18, 2026 for Aayush Agrawal, ....
Pls find enclosed Intimation w.r.t Participation in Investor Conference.
Pls find enclosed newspaper publication for transfer of equity shares to IEPF.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 27, 2026 for Aayush Agrawal, trustee ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 19, 2026 for Ravi Agrawal, trustee ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Ravi Agrawal, trustee ....
Results of 30.06.2026.
PFA Dividend Intimation
PFA record date intimation
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 29, 2026 for Aayush Agrawal, trustee ....
Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve Update on board meeting
Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve Financial Results for the quarter ....
Pls find enclosed voting and scrutinizer''s report w.r.t to 47th AGM held on 16.07.2026.
Pls find enclosed AGM Proceedings
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 14, 2026 for Ravi Agrawal, trustee ....
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 08, 2026 for Aayush Agrawal, ....
Pls find enclosed Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30.06.2026.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 03, 2026 for Aayush Agrawal Trust ....
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship Ltd
Pls find enclosed Reg 30 Intimation.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 01, 2026 for Ravi Agrawal, trustee ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 26, 2026 for Ravi Agrawal, trustee ....
Pls find enclosed Trading Window Closure Notice.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 19, 2026 for Ravi Agrawal, trustee ....
Pls find enclosed newspaper publication of AGM Notice
Pls find enclosed BRSR for FY 2026.
Pls find enclosed herewith Annual Report for FY 2025-2026.
Pls find enclosed notice published in newspapers intimating that the 47th AGM of the Company will be held on 16th July 2026.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 15, 2026 for Aayush Agrawal, trustee ....
Pls find enclosed herewith AGM Intimation
Pls find enclosed intimation w.r.t participation in investor conference
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 08, 2026 for Gabs Investments Pvt Ltd
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 08, 2026 for Aayush Agrawal, trustee ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ravi Agrawal, Trustee Ravi Agrawal Trust
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 02, 2026 for Ravi Agrawal, trustee ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 28, 2026 for Aayush Agrawal, trustee ....
Pls find enclosed revised Intimation w.r.t Participation in Investor Conference
Please find enclosed Intimation w.r.t Participation in Investor Conference.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 13, 2026 for Aayush Agrawal, trustee ....
Pls find enclosed submission of Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Reg 24A of LODR.
Pls find enclosed Written Transcript of Earnings Call held on 5th May 2026.
Please find enclosed the Newspaper Publication of Financial Results for the quarter and year ended 31st March 2026
Annual Reports
16Credit Ratings
6Concalls
36Jan 2026
31 Jan 2026Nov 2025
30 Nov 2025Jul 2025
31 Jul 2025Jul 2025
31 Jul 2025Apr 2025
30 Apr 2025Feb 2025
28 Feb 2025Oct 2024
31 Oct 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Jan 2024
31 Jan 2024Oct 2023
31 Oct 2023Jul 2023
31 Jul 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Aug 2022
31 Aug 2022Jan 2022
31 Jan 2022Oct 2021
31 Oct 2021Jul 2021
31 Jul 2021Apr 2021
30 Apr 2021Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Jul 2019
31 Jul 2019Apr 2019
30 Apr 2019Jan 2019
31 Jan 2019Oct 2018
31 Oct 2018Jul 2018
31 Jul 2018May 2018
31 May 2018Jan 2018
31 Jan 2018Oct 2017
31 Oct 2017Aug 2017
31 Aug 2017May 2017
31 May 2017Jan 2017
31 Jan 2017Oct 2016
31 Oct 2016Aug 2016
31 Aug 2016Apr 2016
30 Apr 2016Feb 2016
29 Feb 2016Held by ETFs
25 ETFs hold AJANTPHARM · sorted by weight
Held by Mutual Funds
115 schemes hold AJANTPHARM · sorted by weight